Eligard

ApprovedSmall molecule

HHanAll BioPharma Co., Ltd.

Eligard is one of 73 small molecule programs targeting Central precocious puberty. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Precocious PubertyActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Central Precocious PubertyApproved

Active, not recruiting

Metastatic Prostate CancerApproved

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Eligard

HHanAll BioPharma Co., Ltd.

Approved

4 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Osmitrol

BB. Braun Medical Inc.

Preclinical

—8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedActive, not recruiting

CPP

NCT06926933

Phase 2Recruiting

Prostate Cancer

NCT04249154

Q2 2031

Phase 2Recruiting

Prostate Cancer

NCT06654336

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT06654336·162 enrolled

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

Completed·HHanAll BioPharma Co., Ltd.·Phase 4·NCT01511874·42 enrolled

Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT04249154·77 enrolled

Show 1 more trial

Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Completed·IInstitut Cancerologie de l'Ouest·Phase 2·NCT02274779·74 enrolled

Testosterone1 trial

Evaluate Recovery of Testosterone for Patients Using Eligard

Completed·CChesapeake Urology Research Associates·Phase 4·NCT01136226·42 enrolled

Metastatic Prostate Cancer1 trial

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Terminated· Astellas logo

Astellas·Phase 4·NCT01933022·1 enrolled

CPP1 trial

An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty

Active, not recruiting·HHanAll BioPharma Co., Ltd.·Approved·NCT06926933·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Eligard. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eligard compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eligard. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HanAll BioPharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHanAll BioPharma Co., Ltd.

Eligard

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2031

Trials by Indication[1]

Prostate Cancer4 trials

Testosterone1 trial

Metastatic Prostate Cancer1 trial

CPP1 trial

References

Drug Info

Quick Facts

Related News